WHO Vaccine pipeline review; CDC on impact of COVID on AMR

Dear All,

WHO continues to crank out those pipeline reviews … now we have one for bacterial vaccines! Go here for the press release and here for the report. The report considers data from 2010 forward and (interestingly) provides data on both active and failed projects. The review identified 94 active preclinical candidates and 61 projects in the clinic. The distribution of clinical projects is instructive:

In the figure, BPPL = Bacterial Priority Pathogen List (go here if you need to see the current priority pathogen lists). You can thus see that we have reasonable coverage of Medium and High priority pathogens, but Critical pathogens are not well served.

Unfortunately, that gap in vaccine spectrum is unlikely to be fixed. As the report notes, “six pathogens from the WHO priority pathogens list (A. baumannii, P. aeruginosa, Enterobacter spp., E. faecium, S. aureus, and H. pylori) … were found to have low feasibility for vaccine development due to biological and other product development challenges.” Sad, but true! A real strength of the report is its discussion of the likelihood of success of the various types of projects; for more on feasibility issues, see also this 29 Mar 2021 newsletter on WHO’s Immunization Agenda 2030: A Global Strategy to Leave No One Behind.


CDC has just released a review on the impact of COVID-19 on AMR. Go here for the press release and here for the report. The key finding can be stated briefly: “resistant hospital-onset infections and deaths both increased at least 15% during the first year of the pandemic.” The results varied somewhat by pathogen (see table at the top of report page 6) with the sharpest increase being a 78% rise in the incidence of carbapenem-resistant Acinetobacter. Ugh!

Sadly, this result would seem predictable based on a prior CDC NHSN report (Weiner-Lastinger 2021, doi:10.1017/ice.2021.362)  showing significant increases during 2020 in rates of central-line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and MRSA bacteremia.

Many thanks to our colleagues at CDC for compiling and sharing these data! Now is the time for action at levels of the AMR ecosystem. Prevention, stewardship, new diagnostics, new therapeutics are needed! Let’s get the PASTEUR Act passed!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Current funding opportunities (most current list is here)


Upcoming meetings of interest to the AMR community (most current list is here):

  • [NEW] 20 Jul 2022 (virtual. 11a-noon ET): Pfizer– and CQ Roll Call-sponsored webinar entitled “Superbugs: Policy Solutions to Tackle an Emerging Health Threat.” This webinar will feature Senators Todd Young (R-IN) and Michael Bennet (D-CO), the senate sponsors of the PASTEUR Act! Don’t miss it! Go here to register.
  • 26 July 2022 (virtual, 10a-11.30a ET): REVIVE webinar entitled “New approaches for antibiotic discovery”. Go here for details. 
  • 24-27 July 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.
  • 28-31 July 2022 (Singapore): 10th International Congress of Asia Pacific Society of Infection Control is a hybrid event for professionals in the Asia Pacific region. Go here for details and to register.
  • 10 Aug 2022 (virtual, 11a-12.30p ET): REVIVE webinar entitled “Animal models to study the activity of antibiotics.” Go here for details. 
  • 10 Aug 2022 (virtual, 10a-4.30p ET): USDA ‘s APHIS (Animal and Plant Health Inspection Service) will host a public meeting on Antimicrobial Resistance. Co-hosted with USDA’s FSIS (Food Safety Inspection Service) and REE (Research, Education and Economics) mission area, the webinar will review lessons learned since the first AMR workshop 2012 as well as discuss plans for the future. Go here to register.
  • 23 August 2022 (virtual, 11a-12.30p ET): REVIVE webinar entitled “The Challenges and options in developing antibiotic combinations.” Go here for details. 
  • 30 August 2022 (virtual, 8.30a-5.00p ET): Webinar sponsored by CDC and FDA entitled “Drug Development Considerations for the Prevention of Healthcare-Associated Infections.” This is very timely as developing products for prevention is surprisingly hard. As just one example, see this 20 Dec 2018 newsletter about a valiant  (but failed, sadly) effort to develop a S. aureus vaccine. Go here for additional details and to register. 
  • 12-13 Sep 2022 (virtual, 9a-5p ET): This meeting of PACCARB is going to “identify key issues and critical policy gaps through a series of facilitated discussions examining a hypothetical large-scale disease outbreak scenario based on historic examples and estimates of future AMR outbreaks.” Sounds like pandemic wargaming (Center for Health Security; pre-COVID 19 May 2020 NPR article) to me! Go here for details.
  • 20-24 Sep 2022 (New Delhi): 21st Congress of the International Society for Human and Animal Mycology (ISHAM). Go here for details.
  • 4-7 Oct 2022 (Dublin, Ireland): The 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. This is an excellent meeting, especially for developers … and if you’ve missed it, the recordings from the 2021 meeting are online. Go here for details on the 2022 meeting.
  • 19-23 Oct 2022 (Washington, DC): IDWeek 2022, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Go here for details.
    • [NEW] IDWeek has opened pipeline sessions for antibacterials, antifungals, and non-HIV, non-COVID antivirals as well as for diagnostics (no limitations). Go here to submit your abstract; this 14 July 2022 newsletter contains some additional details.
  • 15-23 Oct 2022 (in person, residential, Les Pensières, Veyrier-du-Lac, France): The 6th edition of Patrice Courvalin’s fabulous ICARe residential training course covering all things AMR is on for 2022! This is a soup-to-nuts training in AMR: it is very intense, very detailed, and always gets rave reviews from attendees. Registration is open 21 Mar 2022 to 21 June 2022 and is limited, so book your slot as soon as you can. Go here for details.
  • 19-23 Oct 2022 (Washington, DC): IDWeek 2022, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Go here for details.
  • [NEW] 23 Oct 2022 (Cape Town, South Africa): Symposium entitled “Tackling AMR: How implementation research is vital in a One Health approach” that is sponsored by the AMR knowledge hub of TGHN (The Global Health Network). Go here for details.
  • 25-28 Oct 2022 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.
  • 17-20 Nov 2022 (Kuala Lumpur, Malaysia): The International Congress on Infectious Diseases will take place for the first time as a hybrid event. Go here for details. 
  • 27-30 Nov 2022 (Perth, Australia): 32nd International Congress of Antimicrobial Chemotherapy is the biennial congress of the International Society of Antimicrobial Chemotherapy (ISAC). Go here for details.

Share

EPA (part 5): Interagency Framework on AMR Risks of Antibacterial and Antifungal Pesticides

This is the fifth of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, and a 4th newsletter (27 Jan 2024) containing some additional resources. Dear All, Excitingly, the US EPA

HLM on AMR at UNGA: The end of the beginning

Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. Dear All (and with thanks to Damiano for co-authoring), Last week in NYC, the UN General Assembly (UNGA) and all its surrounding activities created a lot of energy (not to mention a giant traffic jam)! After a series of side meetings

Without action, AMR costs go from $66b to $159b/yr by 2050

Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout

UN TV: You can watch the AMR High-Level Meeting at UNGA

Dear All, The AMR HLM (High-Level Meeting) at the UN General Assembly starts at 10a ET today.  You can watch it here on UN TV: https://webtv.un.org/en/asset/k11/k11knc6w2t Addendum: It’s available for replay at that same link. See also the 1 Oct 2024 newsletter for a review of the HLM. All best wishes, –jr John H. Rex, MD

Scroll to Top